Phase 3 study for people with Macular Degeneration

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 15 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor Merck Sharp & Dohme LLC
Registry number NCT07705555
Started 27 August 2026 Today 16 October 2026 Estimated completion 31 October 2028

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Eyeclinic Albury-Wodonga ( Site 2204) Albury NSW Recruiting
Sydney Retina Clinic and Day Surgery ( Site 2203) Sydney NSW Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 15 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 960

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Has Type 1 or Type 2 diabetes mellitus and a hemoglobin A1c (HbA1c) of ≤12%

* Has a decrease in vision in the study eye determined by the Investigator to be primarily the result of diabetic macular edema (DME)

* For participants who are treatment-naïve for DME, the diagnosis must have been made within 9 months of screening. For all treatment-experienced participants, the first treatment should have been no longer than 3 years prior to the Screening visit

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Has had renal failure requiring renal transplant, hemodialysis, or peritoneal dialysis or has renal failure anticipated to require hemodialysis or peritoneal dialysis at any time during the study

* Has history of stroke (cerebral vascular accident) or myocardial infarction within 180 days to first dose of study intervention

* Has newly diagnosed or previously untreated diabetes mellitus and initiated oral or injectable anti-diabetic medication within 3 months to first dose of study intervention

* Has history of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of screening

* Has any treatment for complications of cataract surgery with steroids or yttrium aluminum garnet (YAG) laser capsulotomy in the study eye within 90 days of screening

* Has advanced or uncontrolled glaucoma in the study eye

* Has any history of retinal detachment or treatment or surgery for retinal detachment in the study eye

* Has active retinal disease other than the condition under investigation in the study eye

* Has uncontrolled blood pressure at screening

Dates on the record

Started 27 August 2026
Estimated completion 31 October 2028
Registry last updated 9 October 2026
Checked by Voxsanity 15 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 9 October 2026.
  • This page last checked by Voxsanity: 15 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.